Trial Profile
Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 May 2018 Status changed from completed to discontinued.
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 29 Dec 2016 Planned End Date changed from 1 Jul 2019 to 1 Feb 2017.